BASEL, Switzerland, May 20, 2003 (PRIMEZONE) -- Novartis (NYSE:NVS)(Other OTC:NVSEF):
New data from a large pivotal US trial demonstrates Zelmac(R) (tegaserod) was significantly more effective than placebo in providing rapid and sustained relief from chronic constipation based on a trial of more than 1,300 patients. Furthermore, Zelmac provided relief of several chronic constipation symptoms including bowel movement frequency, straining, stool consistency, abdominal discomfort or pain, bloating or distension.
Please find press release as pdf under the following linkhttp://reports.huginonline.com/904623/118373.pdf